e-Therapeutics plc Company Profile (LON:ETX)

About e-Therapeutics plc (LON:ETX)

e-Therapeutics plc logoe-Therapeutics plc is a United Kingdom-based drug discovery and development company. The Company's discovery platform is based on the network of pharmacology and chemical biology. The Company operates in the business segment of drug discovery and development. The Company applies its platform to the discovery of new drug candidates. The therapeutic focus of the Company's discovery activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and antivirals. The Company generates a range of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule antiTNFα; ETS2400, in Hedgehog pathway inhibition, and ETS5200, which delivers a range of spectrum antivirals. The Company has completed a Phase IIb study of a drug candidate for depressive disorder, ETS6103, as well as Phase I clinical trials in cancer for ETS2101.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: LON:ETX
  • CUSIP: N/A
  • Web: www.etherapeutics.co.uk/
  • Market Cap: £28.53 million
  • Outstanding Shares: 268,471,000
Average Prices:
  • 50 Day Moving Avg: GBX 10.66
  • 200 Day Moving Avg: GBX 10.28
  • 52 Week Range: GBX 6 - GBX 13.13
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: GBX 0.05 per share
  • Price / Book: 2.17
  • EBITDA: ($9,000,000.00)
  • Return on Equity: -40.76%
  • Return on Assets: -37.10%
  • Average Volume: 245,200 shs.

Frequently Asked Questions for e-Therapeutics plc (LON:ETX)

What is e-Therapeutics plc's stock symbol?

e-Therapeutics plc trades on the London Stock Exchange (LON) under the ticker symbol "ETX."

Who are some of e-Therapeutics plc's key competitors?

Who are e-Therapeutics plc's key executives?

e-Therapeutics plc's management team includes the folowing people:

  • Iain Gladstone Ross, Executive Chairman of the Board
  • Raymond John Barlow, Chief Executive Officer, Director
  • Steven Medlicott, Chief Financial Officer, Interim Chief Operating Officer, Director
  • Trevor M. Jones Ph.D., CBE, Non-Executive Director
  • Bradley Richard Hoy, Independent Non-Executive Director

How do I buy e-Therapeutics plc stock?

Shares of e-Therapeutics plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is e-Therapeutics plc's stock price today?

One share of e-Therapeutics plc stock can currently be purchased for approximately GBX 10.63.

MarketBeat Community Rating for e-Therapeutics plc (LON ETX)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  117
MarketBeat's community ratings are surveys of what our community members think about e-Therapeutics plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for e-Therapeutics plc (LON:ETX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for e-Therapeutics plc (LON:ETX)
Price Target History for e-Therapeutics plc (LON:ETX)
Analysts' Ratings History for e-Therapeutics plc (LON:ETX)
No equities research coverage for this company has been tracked by MarketBeat.com


Earnings History for e-Therapeutics plc (LON:ETX)
No earnings announcements for this company have been tracked by MarketBeat.com


Earnings Estimates for e-Therapeutics plc (LON:ETX)
Current Year EPS Consensus Estimate: $-3.600 EPS


Dividend History for e-Therapeutics plc (LON:ETX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for e-Therapeutics plc (LON:ETX)
Insider Trades by Quarter for e-Therapeutics plc (LON:ETX)
Insider Trades by Quarter for e-Therapeutics plc (LON:ETX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2017Iain Gladstone RossInsiderBuy250,000GBX 11£27,500
7/3/2017Trevor Mervyn JonesInsiderBuy45,364GBX 1,213£550,265.32
6/1/2017Steve MedlicottInsiderBuy1,000,000GBX 6£60,000
5/12/2017Trevor Mervyn JonesInsiderBuy59,400GBX 8£4,752
1/3/2017Trevor Mervyn JonesInsiderBuy36,917GBX 7£2,584.19
1/21/2015Steve MedlicottInsiderBuy150,000GBX 25.25£37,875
(Data available from 1/1/2013 forward)


Headline Trends for e-Therapeutics plc (LON:ETX)
Latest Headlines for e-Therapeutics plc (LON:ETX)
Loading headlines, please wait.


Social activity is not available for this stock.


e-Therapeutics plc (ETX) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.